Skip to main content

Frontier Says HIV Therapy Effective in Difficult-to-Treat Patients

Nanjing Frontier Biotech announced positive top-line results from a China Phase III trial of its long-acting two-drug therapy for AIDS. In the trial, Frontier's once-weekly Aikening® (albuvirtide) plus lopinavir (LPV) showed it was not inferior to a lopinavir three-drug arm in an Asian population that had failed initial treatment. Two NRTIs were replaced with Aikening® in the combination therapy, which produced rapid and persistent viral suppression. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.